{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.1","upperLimit":"86.8","value":"69.9"},{"groupId":"OG001","lowerLimit":"58.6","upperLimit":"96.4","value":"83.3"},{"groupId":"OG002","lowerLimit":"43.0","upperLimit":"85.4","value":"66.7"},{"groupId":"OG003","lowerLimit":"48.8","upperLimit":"90.9","value":"73.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"description":"Percentages of patients with responses after radiation therapy (induction therapy) are reported with 95% confidence intervals. Complete and partial responses were considered responses. SPNET is no longer recognized by WHO (World Health Organization) as a disease entity. Additional trial information can be found under PubMed® # 30332335.","dispersionType":"95% Confidence Interval","groups":[{"description":"SPNET patients who received regimen A (no carboplatin / no isotretinoin)","id":"OG000","title":"Regimen A (SPNET Patients)"},{"description":"SPNET patients who received regimen B (carboplatin / no isotretinoin)","id":"OG001","title":"Regimen B (SPNET Patients)"},{"description":"SPNET patients who received regimen C (no carboplatin / isotretinoin)","id":"OG002","title":"Regimen C (SPNET Patients)"},{"description":"SPNET patients who received regimen D (carboplatin / isotretinoin)","id":"OG003","title":"Regimen D (SPNET Patients)"}],"paramType":"NUMBER","populationDescription":"23 of 23 eligible Arm A SPNET patients were evaluated for response after induction, as were 18/19, 21/21, and 19/22 arm B, C, and D patients, respectively.","reportingStatus":"POSTED","timeFrame":"12 weeks after treatment initiation","title":"Tumor Response to Radiation Therapy for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}